<!DOCTYPE html><html><head><title> Pacifica Code Section 26-61-S202 </title><link rel="stylesheet" href="../../../assets/style.css"/></head><body>
<b><i>
                      Effective 5/4/2022</i></b>
<br>
<b>26-61-202.&nbsp;
          </b><b>Duties.</b>
<br>
<a id="26-61-202(1)" name="26-61-202(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
The board shall review any available scientific research related to the human use of cannabis, a cannabinoid product, or an expanded cannabinoid product that:
<a id="26-61-202(1)(a)" name="26-61-202(1)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
was conducted under a study approved by an IRB;</td>
</tr>
</tbody></table>
<a id="26-61-202(1)(b)" name="26-61-202(1)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
was conducted or approved by the federal government; or</td>
</tr>
</tbody></table>
<a id="26-61-202(1)(c)" name="26-61-202(1)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%"><a id="26-61-202(1)(c)(i)" name="26-61-202(1)(c)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
was conducted in another country; and</td>
</tr>
</tbody></table>
<a id="26-61-202(1)(c)(ii)" name="26-61-202(1)(c)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
demonstrates, as determined by the board, a sufficient level of scientific reliability and significance to merit the board's review.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61-202(2)" name="26-61-202(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
Based on the research described in Subsection <a href="#26-61-202(1)">(1)</a>, the board shall evaluate the safety and efficacy of cannabis, cannabinoid products, and expanded cannabinoid products, including:
<a id="26-61-202(2)(a)" name="26-61-202(2)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
medical conditions that respond to cannabis, cannabinoid products, and expanded cannabinoid products;</td>
</tr>
</tbody></table>
<a id="26-61-202(2)(b)" name="26-61-202(2)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
cannabis and cannabinoid dosage amounts and medical dosage forms;</td>
</tr>
</tbody></table>
<a id="26-61-202(2)(c)" name="26-61-202(2)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
interaction of cannabis, cannabinoid products, and expanded cannabinoid products with other treatments; and</td>
</tr>
</tbody></table>
<a id="26-61-202(2)(d)" name="26-61-202(2)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
contraindications, adverse reactions, and potential side effects from use of cannabis, cannabinoid products, and expanded cannabinoid products.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61-202(3)" name="26-61-202(3)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(3)</td><td style="width:99%">
Based on the board's evaluation under Subsection <a href="#26-61-202(2)">(2)</a>, the board shall develop guidelines for treatment with cannabis, a cannabinoid product, and an expanded cannabinoid product that include:
<a id="26-61-202(3)(a)" name="26-61-202(3)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
a list of medical conditions, if any, that the board determines are appropriate for treatment with cannabis, a cannabis product, a cannabinoid product, or an expanded cannabinoid product;</td>
</tr>
</tbody></table>
<a id="26-61-202(3)(b)" name="26-61-202(3)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
a list of contraindications, side effects, and adverse reactions that are associated with use of cannabis, cannabinoid products, or expanded cannabinoid products;</td>
</tr>
</tbody></table>
<a id="26-61-202(3)(c)" name="26-61-202(3)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
a list of potential drug-drug interactions between medications that the United States Food and Drug Administration has approved and cannabis, cannabinoid products, and expanded cannabinoid products; and</td>
</tr>
</tbody></table>
<a id="26-61-202(3)(d)" name="26-61-202(3)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
any other guideline the board determines appropriate.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61-202(4)" name="26-61-202(4)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(4)</td><td style="width:99%">
The board shall submit the guidelines described in Subsection <a href="#26-61-202(3)">(3)</a> to the director of the Division of Professional Licensing.</td>
</tr>
</tbody></table>
<a id="26-61-202(5)" name="26-61-202(5)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(5)</td><td style="width:99%">
Guidelines that the board develops under this section may not limit the availability of cannabis, cannabinoid products, or expanded cannabinoid products permitted under <a href="../../Title4/Chapter41A/4-41a.html?v=C4-41a_2018120320181203">Title 4, Chapter 41a, Cannabis Production Establishments</a>, or <a href="../../Title26/Chapter61A/26-61a.html?v=C26-61a_2018120320181203">Title 26, Chapter 61a, Utah Medical Cannabis Act</a>.</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=415&amp;sess=2022GS">415</a>, 2022 General Session<br>
</body></html>